Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF R2

VEGF R2

Brief Information

Name:Vascular endothelial growth factor receptor 2
Target Synonym:EC:2.7.10.1,KDR,Vascular endothelial growth factor receptor 2,Fetal liver kinase 1,Kinase insert domain receptor,Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase),Protein-Tyrosine Kinase Receptor Flk-1,FLK1,Tyrosine Kinase Growth Factor Receptor,Fetal Liver Kinase-1,Soluble VEGFR2,CD309 Antigen,EC 2.7.10.1,VEGFR-2,CD309,VEGFR,FLK-1,Vascular Endothelial Growth Factor Receptor-2,VEGFR2,EC 2.7.10
Number of Launched Drugs:15
Number of Drugs in Clinical Trials:42
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

KDR-HP227-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-VEGFR2 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human VEGF R2, His Tag (Cat. No. KDR-HP227) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

KDR-H82E5-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of anti-VEGF R2 CAR-293 cells were stained with 100 μL of 3 μg/mL of Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No.KDR-H82E5) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).

VE2-M5258-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Mouse VEGF164, His,Avitag (Cat. No. VE4-M82Q3) on SA Biosensor, can bind Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE2-M5258) with an affinity constant of 1.33 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

KDR-H82E5-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) on SA Biosensor, can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 482 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

KDR,CD309,FLK1,VEGFR,VEGFR2

Background

Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and  is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tivozanib AV-951; KRN-951; ASP-4130; Kil-8951 Approved Kyowa Hakko Kirin Co Ltd Fotivda United States Carcinoma, Renal Cell Aveo Pharmaceuticals Inc 2017-08-24 Solid tumours; Carcinoma, Renal Cell; Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung Details
Apatinib Mesylate YN-968D1 Approved Advenchen Laboratories 艾坦, Aitan Mainland China Stomach Neoplasms Jiangsu shengdi Medicine Co Ltd 2014-10-17 Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma Details
Midostaurin PKC-412; PKC-412A; CGP-41231; CGP-41251 Approved Novartis Pharma Ag Rydapt EU Leukemia, Myeloid, Acute; Mastocytosis Novartis Europharm Ltd 2017-04-28 Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis Details
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Pain; Esophageal Neoplasms; Glioblastoma; Kidney Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Pazopanib Hydrochloride GW-786034; SB-786034; GSK-786034; GW-786034B Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Patorma, Votrient Mainland China Carcinoma, Renal Cell Novartis Pharma Schweiz Ag 2009-10-19 Osteosarcoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Glioma; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Sarcoma; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Hemangiosarcoma; Carcinoma, Renal Cell; Solid tumours; Chondrosarcoma; Telangiectasia, Hereditary Hemorrhagic Details
Axitinib PF-01367866; AG-13736; AG-013736; CLS-AX Approved Pfizer Pharmaceuticals Ltd (China) Inlyta, 英立达 Mainland China Carcinoma, Renal Cell Pfizer Europe Ma Eeig 2012-01-27 Hepatic Insufficiency; Melanoma; Adenocarcinoma; Macular Degeneration; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Leukemia, Myeloid, Acute; Lung Neoplasms; Thyroid Neoplasms; Solid tumours; Endometriosis; Myelodysplastic Syndromes; Skin Neoplasms; Carcinoma, Renal Cell; Carcinoma; Kidney Neoplasms; Ovarian Neoplasms Details
Regorafenib DAST; BAY-73-4506 Approved Bayer Ag Resihance, Stivarga Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Solid tumours; Carcinoma, Renal Cell; Rectal Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Fruquintinib HMPL-013 Approved Hutchison Medipharma Ltd 爱优特, Elunate Mainland China Colorectal Neoplasms Hutchison Huangpu Medicine (Shanghai) Co Ltd 2018-09-04 Solid tumours; Rectal Neoplasms; Esophageal Neoplasms; Colonic Neoplasms; Kidney Diseases; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Lenvatinib Mesylate MK-7902; ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 Japan Endometrial Neoplasms Eisai Co Ltd 2015-02-13 Liver Diseases; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Lymphoma; Thyroid Neoplasms; Endometrial Neoplasms; Hepatic Insufficiency; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Biliary Tract Neoplasms Details
Ramucirumab IMC-1121; IMC-1C11; LY-3009806; IMC-1121-B; BLA-125477 Approved Dyax Pharma Cyramza United States Carcinoma, Hepatocellular Eli Lilly And Company 2014-04-21 Peritoneal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Urethral Neoplasms; Lymphoma, Mantle-Cell; Cholangiocarcinoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Urologic Neoplasms; Microsatellite instability-high cancer; Ureteral Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Neoplasm Metastasis; Melanoma; Ovarian Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Desmoplastic Small Round Cell Tumor; Carcinoid Tumor; Rectal Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Liver Neoplasms; Skin Melanoma; Biliary Tract Neoplasms; Solid tumours Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef Mainland China Idiopathic Pulmonary Fibrosis Boehringer Ingelheim International Gmbh 2014-10-15 Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Scleroderma, Systemic; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Multiple Myeloma; Prostatic Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Small Cell Lung Carcinoma Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Endometrial Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Sarcoma, Alveolar Soft Part; Gallbladder Neoplasms; Medullary thyroid cancer (MTC); Thyroid Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Osteoma; Carcinoma, Renal Cell; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Thoracic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Genital Diseases, Female; Leiomyosarcoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Neuroendocrine Tumors; Sarcoma; Bile Duct Diseases Details
Vandetanib AZD-6474; CH-331; ZD-6474 Approved Astrazeneca Pharmaceutical Co Ltd Zactima, Caprelsa Japan Medullary thyroid cancer (MTC) Astrazeneca Pharmaceutical Co Ltd 2011-04-06 Solid tumours; Multiple Myeloma; Mesothelioma; Breast Neoplasms; Medullary thyroid cancer (MTC); Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Neuroendocrine; Thyroid Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis Details
Sorafenib Tosylate NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 Approved Onyx Pharmaceuticals Inc 多吉美, Nexavar EU Thyroid Neoplasms Bayer Ag 2005-12-01 Breast Neoplasms; Neoplasm Metastasis; Fasting; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Thyroid Neoplasms; Hepatitis C; Hepatitis B; Liver Neoplasms; Liver Diseases; Pancreatic Neoplasms; Kidney Diseases; Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Solid tumours; Ovarian Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive Details
Sunitinib Malate PHA-290940; SU-010398; SU-11248; GB-102; PNU-290940; SU-011248-L-malate salt; PNU-290940AD; PHA-290940AD Approved Pfizer Pharmaceuticals Ltd (China) Sutent, 索坦 Japan Pancreatic neuroendocrine tumors (pNET) Pfizer Inc 2006-01-26 Breast Neoplasms; Retinal Vein Occlusion; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Macular Degeneration; Carcinoma, Hepatocellular; Urogenital Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Diabetic macular oedema; Prostatic Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Urologic Diseases; Kidney Diseases; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Stomach Neoplasms; Carcinoma, Islet Cell; Carcinoma, Renal Cell; Liver Neoplasms; Solid tumours Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Cediranib AZD2171; AZD-2171; NSC-732208 Phase 2 Clinical Astrazeneca Plc Glioblastoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Hepatic Insufficiency; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Biliary Tract Neoplasms; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Liver Neoplasms; Leukemia; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms Details
Kanitinib CX-1003 Phase 1 Clinical Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd Solid tumours; Esophageal Neoplasms; Prostatic Neoplasms Details
VEGFR-1/2 peptide vaccine (Keio University) Phase 2 Clinical Keio University Neurofibromatoses; Brain Neoplasms; Glioma Details
Glesatinib MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly Phase 2 Clinical Mirati Therapeutics Carcinoma, Non-Small-Cell Lung Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Thymus Neoplasms; Genital Neoplasms, Female; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Metatinib Trometamol BMS-817378; SIM-817378 Phase 1 Clinical Bristol-Myers Squibb Company Liver Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Olinvacimab SSS-23; TTAC-0001 Phase 2 Clinical Pharmabcine Glioblastoma; Triple Negative Breast Neoplasms; Neoplasm Metastasis Details
PZ-1 PZ-1 Phase 1 Clinical Chongqing University Of Arts And Sciences Solid tumours Details
SOMCL-15-290 SOMCL-15-290 Phase 1 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Carcinoma, Squamous Cell Details
PAN-90806 CP-632; OSI-632; CP-547632; PAN-90806 Phase 2 Clinical Pfizer Inc, Osi Pharmaceutical Ovarian Neoplasms; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Macular Degeneration; Diabetic Retinopathy Details
LMV-12(HE003) LMV-12(HE003) Phase 1 Clinical Nanchang Hongyi Technology Co Ltd Solid tumours Details
Recombinant anti-VEGFR2 chimeric monoclonaly antibody (GeneScience) Phase 2 Clinical Changchun Genescience Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
VEGFR2 peptide vaccine (VAXIMM) VXM-01 Phase 2 Clinical Merck Serono Pancreatic Neoplasms; Glioblastoma; Colorectal Neoplasms Details
CEP-11981 ESK-981; CEP-11981; SSR-106462; BOL-303213X Phase 2 Clinical Sanofi Prostatic Neoplasms Details
Ramucirumab biosimilar (CTTQ) Phase 1 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Recombinant human anti-VEGFR2 monoclonal antibody (Buchang Pharma) BC-001 Phase 1 Clinical Shandong Buchang Pharmaceuticals Co Ltd Solid tumours Details
Altiratinib DP-5164; DCC-2701; DCC-22701; T-678746713 Phase 1 Clinical Deciphera Solid tumours; Neoplasms Details
MSB-0254 MSB-0254 Phase 1 Clinical Mabspace Biosciences Co Ltd Solid tumours Details
AXT-107 AXT-107 Phase 2 Clinical AsclepiX Therapeutics Inc Diabetic macular oedema; Macular Degeneration Details
VEGFR2 peptide vaccine (Tokyo University) Phase 1 Clinical University Of Tokyo Pancreatic Neoplasms Details
AVI-3207 AVI-3207 Phase 1 Clinical Avixgen Macular Degeneration Details
Sitravatinib MG-516; MG-91516; MGCD-516; IND-155305 Phase 3 Clinical Mirati Therapeutics Solid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Hepatic Insufficiency; Ureteral Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular Details
FNX-006 FNX-006 Phase 1 Clinical Sichuan University, Chengdu Fannuoxi Biomedical Technology Co Ltd Triple Negative Breast Neoplasms; Melanoma Details
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 Phase 1 Clinical Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms Details
BR-55 BR-55 Phase 2 Clinical Sonus Pharmaceuticals Ovarian Neoplasms; Prostatic Neoplasms; Diagnostic agents Details
Ramucirumab biosimilar (Henlius) HLX-12 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Pamufetinib TAS-115 Phase 1 Clinical Neoplasms Details
Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical) Phase 1 Clinical Sichuan Kelun Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Telatinib EOC-315; BAY-57-9352 Phase 2 Clinical Bayer Ag Solid tumours; Stomach Neoplasms Details
Hydroxychloroquine/Sorafenib Phase 1 Clinical Vg Life Sciences Ovarian Neoplasms Details
QBH-196 QBH-196 Phase 1 Clinical Shenyang Pharmaceutical University Solid tumours; Stomach Neoplasms Details
Tafetinib Malate SIM-0702; SIM-1005; SIM-010603 Phase 1 Clinical Jiangsu Xiansheng Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
KC1036 KC1036; KC-1036 Phase 1 Clinical Beijing Konruns Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours Details
Ningetinib Tosylate CT-053; CT-053-PTSA Phase 2 Clinical Hec Pharm Co Ltd Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
LM-061 LM-061 Phase 2 Clinical Shanghai Lixin Pharmaceutical Research and Development Co Ltd Congenital Hyperinsulinism; Solid tumours Details
KDR2-2 Phase 2 Clinical Guangzhou Huiborui Biomedical Technology Co Ltd Glaucoma, Neovascular; Corneal Neovascularization Details
Brivanib Alaninate ZL-2301; BMS-540215; BMS-582664 Phase 2 Clinical Bristol-Myers Squibb Company Liver Neoplasms; Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Sarcoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Gastrointestinal Neoplasms Details
Pulocimab AK-109 Phase 2 Clinical Kang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma Details
Chiauranib CS-2164 Phase 3 Clinical Shenzhen Chipscreen Biosciences Co Ltd Solid tumours; Ovarian Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular Details
Famitinib Malate SHR-1020 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Fallopian Tube Neoplasms; Urogenital Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Gastrointestinal Stromal Tumors; Ovarian Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Nasopharyngeal Carcinoma; Idiopathic Pulmonary Fibrosis; Nasopharyngeal Neoplasms; Carcinoma, Transitional Cell; Pancreatic neuroendocrine tumors (pNET); Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours Details
JY-025 JY-025 Phase 3 Clinical Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
MG-D-1609 MG-D-1609 Phase 2 Clinical Metagone Biotech Solid tumours Details
Sorafenib/MG-005 MGD-1509; MG-D-1509 Phase 1 Clinical Metagone Biotech, Tri-Service General Hospital Solid tumours Details
Gentuximab Phase 1 Clinical Genescience Pharmaceuticals Co Ltd Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message